Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity

Ichinose, Masakazu; Minakata, Yoshiaki; Motegi, Takashi; Ueki, Jun; Gon, Yasuhiro; Seki, Tetsuo; Anzai, Tomohiro; Nakamura, Shuhei; Hirata, Kazuto

doi:10.2147/copd.s166023

Cited by 26 publications

(40 citation statements)

References 27 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 A previous study reported a slight improvement in physical activity of more than moderate intensity following dual-bronchodilator tiotropium/olodaterol compared to mono-bronchodilator tiotropium. 11 COPD patients who participated in the SCOPE study were mostly characterized by moderate COPD with mild symptoms. Interestingly, it was predicted that physical activity with moderate to vigorous intensity would improve due to mild symptoms, and indeed, a reduction of time for physical activity at 1.0–1.5 METs was observed.…”

Section: Discussionmentioning

confidence: 99%

<p>First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease</p>

Takahashi

Uchida²,

Kato

et al. 2020

COPD

View full text Add to dashboard Cite

Background Comparative effects on physical activity of mono and dual bronchodilators remain unclear in patients with treatment-naïve chronic obstructive pulmonary disease (COPD). We sought to compare the changes in physical activity before and after tiotropium and tiotropium/olodaterol treatment in treatment-naïve COPD patients. Methods A prospective, multicenter, randomized, open-labeled, and parallel interventional study was conducted. Eighty Japanese patients with treatment-naïve COPD were randomized to receive either tiotropium or tiotropium/olodaterol treatment for 12 weeks. Spirometry and dyspnea index were assessed, and COPD assessment test (CAT) and the 6-minute walk distance (6MWD) were conducted before and after treatment. Evaluation of physical activity was assessed by a triaxle accelerometer over a 2-week period before and after treatment. Results There were no differences in the mean age (69.8 vs 70.4 years), body mass index (BMI) (22.5 vs 22.6 kg/m 2 ) and mean % forced expiratory volume in 1 second (%FEV1) at baseline (61.5 vs 62.6%) between the two groups. Changes in FEV1 (mean±standard error, 242.8±28.8 mL) and transient dyspnea index (TDI) (2.4±0.3 points) before and after tiotropium/olodaterol treatment were greater than with tiotropium treatment (104.1±31.9 mL, p<0.01 and 1.5±0.3, p=0.02, respectively). Changes in the duration of physical activity with 1.0–1.5 metabolic equivalents (METs) estimated in the sedentary position following tiotropium/olodaterol treatment (−38.7±14.7 min) tended to be reduced more than with tiotropium treatment (−4.6±10.6 min) (p=0.06), although those with ≥2.0 METs numerically increased with both treatments (+10.8±7.6 min for tiotropium/olodaterol vs +8.3±7.6 min for tiotropium, p=0.82). Tiotropium/olodaterol treatment reduced the duration of physical activity with 1.0–1.5 METs (regression coefficient, −43.6 [95% CI −84.1, −3.1], p=0.04) in a multiple regression model adjusted for cofounding factors such as age, FEV1, total CAT scores, 6MWD, and TDI. Conclusion This is the first study to report the impact of dual bronchodilator on physical activity in treatment-naïve COPD patients of Japanese with low BMI.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease</p>

Takahashi

Uchida²,

Kato

et al. 2020

COPD

View full text Add to dashboard Cite

show abstract

“…Based on a postulate of downward spiral of health resulting from curative-intent therapy (E- Figure 1), efforts to improve physical exercise, function, and QoL in lung cancer survivors may need to first optimize medical therapy for cardiopulmonary disease [41] and possibly psychiatric illness [42] to alleviate dyspnea to be effective. Recent randomized controlled trials in COPD patients show that combination bronchodilator inhaler therapy is effective in reducing dyspnea [43] and possibly in improving physical activity [44,45]. Initiation of these inhalers, particularly in survivors with concomitant COPD, may be an important first step.…”

Section: Discussionmentioning

confidence: 99%

Characterization of Dyspnea in Lung Cancer Survivors Following Curative-Intent Therapy

Ries

2018

Preprint

View full text Add to dashboard Cite

word count 250)Purpose Dyspnea is highly-prevalent in lung cancer survivors following curative-intent therapy. We aimed to identify clinical determinants of dyspnea and characterize its relationship with functional exercise capacity (EC). MethodsIn an analysis of data from a cross-sectional study of lung cancer survivors who completed curative-intent therapy for stage I-IIIA disease ≥1 month previously, we tested a thorough list of comorbidities, lung function, and lung cancer characteristics. We assessed dyspnea using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module 13 (LC13) and functional EC the six-minute walk. We verified results with the University of California San Diego Shortness of Breath Questionnaire (SOBQ). ResultsIn 75 participants at a median of 12 months since completing treatment, the mean (SD) LC13-Dyspnea score was 35.3 (26.2); 60% had abnormally-high dyspnea. In multivariable linear regression analyses, significant clinical determinants of dyspnea were [β (95% confidence interval)]: psychiatric illness [-20.8 (-32.4, -9.09) for No/Yes], heart failure with reduced ejection fraction [-15.5 (-28.0, -2.97) for No/Yes], and forced expiratory volume in 1 second [-0.28 (-0.49, -0.06) for each % predicted]. Dyspnea was an independent predictor of functional EC [-1.54 (-2.43, -0.64) for each point]. These results were similar with the SOBQ.Conclusion

show abstract

“…On the other hand, the values of indicators of PA can easily fluctuate based on several factors, in other words, the indicators of PA show poor reproducibility. This might be the reason why the different studies have reported inconsistent results regarding the effects of bronchodilators on PA in COPD patients [31,[39][40][41][42][43][44][45][46][47][48][49][50][51][52]. 'Physical activity' can be defined as "any bodily movement produced by skeletal muscles that results in energy expenditure" [18], but it is usually defined as physically active behavior that is comparable to moderate to vigorous-intensity PA (MVPA) [19,20].…”

Section: Sedentary Behaviormentioning

confidence: 99%

“…Among a total of 392 reports related to the effects of bronchodilators on PA in COPD patients that were registered in the PubMed database from 2005 to 2020, 15 reports that measured PA with an accelerometer were selected ( Figure 3) [31,[39][40][41][42][43][44][45][46][47][48][49][50][51][52]. Among these 15 reports, 8 studies reported that bronchodilators were effective for improving PA, 3 studies reported that some bronchodilators were suggested to be effective by some indicators but not other indicators, and 4 studies reported that bronchodilators were ineffective (Tables 2-4).…”

Section: Effectiveness In Copdmentioning

confidence: 99%

“…Ichinose et al [51] examined the effects of six-week treatment with tiotropium/olodaterol combination or tiotropium in 184 patients with moderate to very severe COPD (FEV1 % predicted: 52.6%, age 72.8 years) using a crossover design. The indicators employed were MVPA, total activity, and step count.…”

Section: Studies Reporting That Bronchodilators Were Ineffectivementioning

confidence: 99%

See 1 more Smart Citation

Data Reproducibility and Effectiveness of Bronchodilators for Improving Physical Activity in COPD Patients

Minakata

Sasaki

2020

JCM

Self Cite

View full text Add to dashboard Cite

Increasing physical activity (PA) in patients with chronic obstructive pulmonary disease (COPD) is an important issue, however, the effect of bronchodilators on PA is still controversial. The indicators of PA, as measured by an accelerometer, can easily fluctuate based on several factors, which might cause inconsistent results. In this review, we listed the indicators of PA and the factors influencing the reproducibility of indicators of PA, and reviewed reports in which the effects of bronchodilators on PA were evaluated by an accelerometer. Then, we investigated the association between the processing of influencing factors and the effectiveness of bronchodilators for improving the PA of COPD patients. Fifteen reports were extracted using the PubMed database. In all seven reports in which adjustment was performed for at least two of four influencing factors (non-wear time, data from days with special behavior, environmental factors, and number of valid days required to obtain reproducible data), bronchodilators showed beneficial effects on PA. No adjustment was made for any of these factors in any of the four bronchodilator-ineffective reports. This suggests that the processing of influencing factors to secure reproducibility might affect the results regarding the effectiveness of bronchodilators for improving PA in COPD patients.

show abstract

Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity

Cited by 26 publications

References 27 publications

<p>First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease</p>

<p>First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease</p>

Characterization of Dyspnea in Lung Cancer Survivors Following Curative-Intent Therapy

Data Reproducibility and Effectiveness of Bronchodilators for Improving Physical Activity in COPD Patients

Contact Info

Product

Resources

About